Take­da joins mi­cro­bio­me-fo­cused biotech part­ner's $52.6M raise as it pur­sues more in-house can­cer work

A high-pro­file col­lab­o­ra­tion with Take­da back in late 2018 be­stowed up­on En­terome some phar­ma val­i­da­tion and sig­nif­i­cant cash — $50 mil­lion up­front and an­oth­er $15 mil­lion in R&D cost off­set — to fund its mi­cro­bio­me plat­forms. It al­so rep­re­sent­ed the last of such li­cens­ing deals you’ll like­ly see from the French biotech in a while.

In the first fi­nanc­ing since 2017, En­terome has topped up its re­serves to $52.6 mil­lion (€46.3 mil­lion), most of which is go­ing to the first-in-hu­man stud­ies of its can­cer im­munother­a­py in re­cur­rent glioblas­toma and adren­al tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.